Alex Hirose, PA-C, MS

Publications

• JADPRO-2017-0046.R1. Iron Overload in Myelodysplastic Syndromes (MDS): Pathophysiology, Consequences, Diagnosis, and Treatment. Accepted (06-Jan-2018). Awaiting Production Checklist
• Lyle, L. Hirose, A. (2018) Iron Overload in Myelodysplastic Syndromes (MDS): Pathophysiology, Consequences, Diagnosis, and Treatment. Journal of the Advanced Practitioner in Oncology. Vol 9. No. 4. Pp 357-452.
• Winters A, Gutman JA, Purev E, Stevens E, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, Monson N, Rahkola S, Wright S, D'Ovidio T, Smith C, Jordan C, Pollyea D. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood (2019) 134 (Supplement 1): 2638.

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court
3rd floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-6400

Hospital Affiliation

• University of Colorado Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Hematology
• Hematology and Oncology